Drug Trial Radar · NCT03525613
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
637
Actual
Start
Aug 31, 2018
Primary completion
Jun 28, 2021
Study completion Jun 28, 2022
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
Conditions
- Geographic Atrophy
Interventions
APL-2Drug
Complement (C3) Inhibitor
APL-2Drug
Complement (C3) Inhibitor
Sham ProcedureOther
Subjects will receive a Sham procedure every month
Sham ProcedureOther
Subjects will receive a Sham procedure every other month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12Time frame: Baseline (screening) and Month 12
Locations
112 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Retina & Vitreous Consultants
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retina Vitreous Associates Medical Group
Beverly Hills, California
Retinal Diagnostic Center
Campbell, California
Retina Consultants of Orange County
Fullerton, California
Atlantis Eyecare
Huntington Beach, California
University of California, San Diego, Jacobs Retina
La Jolla, California
Byers Eye Institute at Stanford, Stanford School of Medicine
Palo Alto, California
Doheny Eye Center UCLA
Pasadena, California
Retina Consultants San Diego
Poway, California
Retinal Consultants Med Group, Inc.
Sacramento, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Southwest Retina Research Center, LLC
Durango, Colorado
Colorado Retina Associates
Golden, Colorado
Retina Group of New England
Waterford, Connecticut
Blue Ocean Clinical Research / The Macula Center
Clearwater, Florida
National Ophthalmic Research Institute (Retina Consultants of Southwest Florida)
Fort Myers, Florida
Bascom Palmer Eye Institute
Miami, Florida
Bascom Palmer Eye Institute of Naples
Naples, Florida
Retina Specialty Institute
Pensacola, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center, PC
Augusta, Georgia
Gailey Eye Clinic Retina Center
Bloomington, Illinois
Northwestern Feinberg School of Medicine
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Midwest Eye Institute
Indianapolis, Indiana
Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky
Lexington, Kentucky
Retina Associates New Orleans
Metairie, Louisiana
The Retina Care Center
Baltimore, Maryland
The Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Center
Hagerstown, Maryland
Mid Atlantic Retina Specialists
Hagerstown, Maryland
Tufts Medical Center
Boston, Massachusetts
New England Retina Consultants
Springfield, Massachusetts
Michigan Medicine Kellogg Eye Center
Ann Arbor, Michigan
Associated Retinal Consultants, P.C
Grand Rapids, Michigan
VitreoRetinal Surgery PA
Minneapolis, Minnesota
Sierra Eye Associates
Reno, Nevada
Retina Center of NJ, LLC
Bloomfield, New Jersey
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.